Description du projet DEENESFRITPL Dispositif basé sur l’aspiration pour remplacer les forceps gynécologiques De nombreuses procédures gynécologiques transcervicales, dont l’insertion du dispositif contraceptif intra-utérin (DIU), impliquent la préhension du col de l’utérus. Celle-ci s’effectue à l’aide de forceps, qui occasionnent cependant une gêne et des saignements. Le projet ASPIVIX, financé par l’UE, a mis au point un nouveau dispositif médical qui recourt à une aspiration délicate pour stabiliser en douceur le col de l’utérus. La conception et les matériaux du dispositif médical Aspivix préviennent les traumatismes et les saignements, rendant l’expérience moins douloureuse pour les patientes. Outre la modernisation des procédures gynécologiques, l’introduction de ce dispositif sur le marché devrait également stimuler l’adoption de la contraception par stérilet et réduire les grossesses non désirées. Afficher les objectifs du projet Masquer les objectifs du projet Objectif For years, gynecologist practices related to Intra-Uterine Contraceptive Device (IUCD) insertions, curettage and several other common indications, have featured poor care and low attention to female patients. The use of the Tenaculum, grasping and pulling on the cervix, inside the vaginal cavity, proved to be painful and traumatic for 84% of the women, and eventually to trigger lesions and bleeding in 29% of the patients, as well as cross-contamination in 5-10% of the women. These disadvantages refrain the use of IUCD contraceptive which exacerbates the unintended pregnancies, sized yearly in 85 mills and representing billions of euros in social costs worldwide.In response, we have developed Aspivix, a new disruptive gynecological device that reduces the pain and eradicates the bleeding during the exploration procedure. Our patented device will replace the Tenaculum forceps, unchanged for over 100 years, to provide gynecologists an easy-to-use device where gentle and firm cervix uterus grasping and traction is needed. Thus, our device will facilitate the adoption of IUCD, which could avoid up to 8% of unintended pregnancies and reduce derived social costs. Besides, Aspivix is intended for a single use which prevents the risk of contamination and cross-infection. Overall, Aspivix has the potential to shorten the intervention procedure (2 steps instead 7), which will represent for the physician a 28% economic benefit. As result, Aspivix will fulfill the needs of more than 64 M of women worldwide/year, a market that is projected to grow at a CAGR2016-2021 of ~6.5% due to the high demand of IUCD insertions and is valued in more than €350M. In this way, thanks to the sales of 22M units in the European, Asian and North American Markets after 5-years, Aspivix will generate cumulative revenues of nearly €80 M and, considering the total investment of €3.6M a return of investment (ROI) of €8.3 per euro invested. Champ scientifique medical and health sciencesclinical medicinegynaecology Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Thème(s) EIC-SMEInst-2018-2020 - SME instrument Appel à propositions H2020-EIC-SMEInst-2018-2020 Voir d’autres projets de cet appel Sous appel H2020-SMEInst-2018-2020-1 Régime de financement SME-1 - SME instrument phase 1 Coordinateur ASPIVIX SA Contribution nette de l'UE € 50 000,00 Adresse CHEMIN DU CLOSEL 5 1020 RENENS Suisse Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Schweiz/Suisse/Svizzera Région lémanique Vaud Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00
